BC030867 Inhibitors
Chemical inhibitors of BC030867 act through various mechanisms to inhibit its function by targeting different signaling pathways and kinases. Staurosporine is a broad-spectrum kinase inhibitor that can prevent the phosphorylation and subsequent activation of BC030867 by blocking the upstream kinases that lead to its activation. LY294002 specifically inhibits PI3K, leading to a decrease in Akt signaling. Since the PI3K/Akt pathway is essential for various cellular functions, the inhibition by LY294002 can prevent the activation of BC030867 that relies on this signaling cascade. Similarly, Rapamycin targets mTOR, a key component of the mTOR signaling pathway, and its inhibitory effect can impair cellular processes that are crucial for the activity of BC030867.
Additionally, PD98059 and U0126 are both MEK inhibitors, which prevent the activation of the ERK pathway, a pathway involved in numerous cellular functions. By inhibiting MEK and the downstream ERK signaling, these chemicals can prevent the functional activation of BC030867 if it requires this pathway. SB203580 specifically inhibits p38 MAP kinase, another pathway that could be critical for BC030867's activity. PP2, as a Src family kinase inhibitor, and Dasatinib, which targets Bcr-Abl and Src family kinases, prevent the phosphorylation of kinases that may be involved in BC030867 activation. Sorafenib, a multi-kinase inhibitor, can block several receptor tyrosine kinases and Raf kinases that may control pathways upon which BC030867 relies for its activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting a broad range of kinases that could be upstream regulators or activators of BC030867, Staurosporine ensures the functional inhibition of BC030867 by preventing its phosphorylation and subsequent activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. Inhibition of PI3K leads to a decrease in Akt signaling, which may be essential for the activation of BC030867. By blocking this pathway, LY294002 can prevent the functional activation of BC030867 that relies on PI3K/Akt-mediated signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR, which is part of the mTOR signaling pathway. Since mTOR can control various cellular functions that might be crucial for the activity of BC030867, the inhibition of mTOR by Rapamycin could result in functional inhibition of BC030867 by impairing processes important for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor which prevents the activation of the ERK pathway. As the ERK pathway is involved in numerous cellular functions, inhibiting MEK and, consequently, the ERK signaling could lead to the functional inhibition of BC030867 if ERK signaling is necessary for BC030867's activation or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting the p38 MAPK pathway, SB203580 could suppress the signaling required for the functional activity of BC030867, assuming that BC030867's activity is dependent on p38 MAPK-mediated signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases can phosphorylate a variety of substrates and are involved in multiple signaling pathways. By inhibiting Src kinases, PP2 could reduce the phosphorylation and activation of signaling pathways that are essential for the functional activity of BC030867. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases and Raf kinases. By inhibiting these kinases, Sorafenib can impede the signaling pathways they control. If BC030867 relies on these pathways for its activation, then Sorafenib's action would lead to the functional inhibition of BC030867. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents ERK phosphorylation. Inhibiting MEK and thus the ERK pathway could potentially lead to the downregulation of signaling processes necessary for the functional activity of BC030867, resulting in its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK signaling can regulate various cellular activities, including those that may involve BC030867. Therefore, by inhibiting JNK, SP600125 could inhibit the functional activity of BC030867 if JNK signaling is required. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 is an Aurora kinase inhibitor. Aurora kinases play a role in cell cycle progression and inhibition of these kinases could affect cellular division and other processes that may be essential for the function of BC030867. Thereby, ZM447439 can functionally inhibit BC030867 by targeting its associated cell cycle pathways. | ||||||